Table 1.
Patients and tumors characteristics by location of aromatase protein expression status at baseline
Characteristics | Aromatase protein expression [n (%)]b | |||
---|---|---|---|---|
Tumor epithelial aromatase | Stromal aromatase | |||
Negative | Positive | Negative | Positive | |
Treatment | ||||
Tamoxifen | 24 (53%) | 72 (49%) | 29 (54) | 63 (48) |
Letrozole | 21 (47%) | 75 (51%) | 25 (46) | 69 (52) |
P-value | 0.6102 | 0.4605 | ||
Age (year) | 66.8 | 67.6 | 67.6 | 67 |
P-valuec | 0.6214 | 0.6969 | ||
Clinical tumor size (cm) | 5.7 | 4.8 | 5.5 | 4.7 |
P-valuec | 0.0144 | 0.0398 | ||
Pre treatment grade | ||||
I | 4 (10%) | 16 (13%) | 4 (8%) | 16 (15%) |
II/III | 38 (90%) | 103 (87%) | 47 (92%) | 90 (85%) |
P-value | 0.5971 | 0.3064 | ||
Pathological tumor size | ||||
≤20 mm | 11 (27%) | 44 (32%) | 11 (27%) | 44 (32%) |
>20 mm | 30 (73%) | 95 (68%) | 30 (73%) | 95 (68%) |
P-value | 0.5567 | 0.5567 | ||
Pathological node status | ||||
Negative | 16 (41%) | 55 (43%) | 21 (47%) | 50 (43%) |
Positive | 23 (59%) | 72 (57%) | 24 (53%) | 65 (57%) |
P-value | 0.8017 | 0.7160 | ||
HER2 statusa | ||||
Negative | 40 (91%) | 140 (95%) | 50 (93%) | 125 (95%) |
Positive | 4 (9%) | 7 (5%) | 4 (7%) | 6 (5%) |
P-value | 0.2806 | 0.4810 | ||
ER statusc | ||||
Negative | 11 (20%) | 12 (8%) | 14 (20%) | 9 (6%) |
Positive | 44 (80%) | 148 (93%) | 55 (80%) | 131 (94%) |
P-value | 0.0098 | 0.0027 | ||
PgR statusc | ||||
Negative | 16 (36%) | 48 (33%) | 20 (37%) | 43 (33%) |
Positive | 28 (64%) | 98 (67%) | 34 (63%) | 87 (67%) |
P-value | 0.6688 | 0.6072 |
aHER2 IHC with fluorescence in situ hybridization confirmation and IHC for ER and PgR were performed as previously described [12]
bAromatase protein expression considered positive if any aromatase IHC staining was present
cFor age and clinical tumor size the student’s t test was used to compare the aromatase positive and negative groups. For binary variables the X2 test was applied with Fisher’s exact test if a count in any cell was less than 5